Lessons from ptie: *be very cautious of phase III trials based on flimsy phase II's (both oxytrex and the ibs drug). This mad rush to go into phase III can be reckless.
I do think remoxy and the abuse proof platform has potential to be a multi product royalty stream for ptie. So all's not lost. Going to take time though, maybe an 08 approval and a couple of years to gain traction.
Market Data 
Markets 
AI
